A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-28

Study Completion Date

2027-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

NCT07036172

Obesity Control

RECRUITING PHASE3

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

NCT06633783

Obesity

NOT_YET_RECRUITING PHASE3

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

NCT05813795

Weight Management

COMPLETED PHASE3

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

NCT06041217

Overweight Obesity

COMPLETED PHASE3

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

NCT05111912

Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this Phase II study, eligible participants will be randomized into one of the two cohorts in a 1:1 ratio to receive once-weekly subcutaneous XW003 injection or semaglutide injection, including a dose-escalation period, a core treatment period and a treatment extension period, for up to 60 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Weight Management

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

XW003

once weekly

Group Type EXPERIMENTAL

XW003 injection

Intervention Type DRUG

Subcutaneous injection

semaglutide

once weekly

Group Type ACTIVE_COMPARATOR

semaglutide injection

Intervention Type DRUG

Subcutaneous injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XW003 injection

Subcutaneous injection

Intervention Type DRUG

semaglutide injection

Subcutaneous injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ecnoglutide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women.
* Weight change of less than 5% within 3 months prior to screening (self-reported).

Exclusion Criteria

* Diagnosis of obesity due to endocrine disorders or a single gene mutation, including but not limited to hypothalamic obesity, pituitary obesity, Cushing's syndrome, hypothyroidic obesity (except for those with normal thyroid function at screening and expected to remain unchanged throughout the trial period after at least 3 months of thyroid hormone replacement therapy), insulinoma, acromegaly.
* History of bariatric surgery or planning to undergo bariatric surgery or use other weight-loss drugs or devices during the trial (except acupuncture for weight loss, liposuction, or abdominal fat removal for more than one year before screening; Except the removal or expulsion of the airbag in the stomach for more than 1 year before screening.
* Diagnosis with any type of diabetes (except gestational diabetes).
* Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening.
* History of acute or chronic pancreatitis or pancreatic injury, history of symptomatic gallbladder disease (except cholecystectomy).
* History of clinically significant gastric emptying abnormalities, such as gastroparesis or gastric outlet obstruction.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No